All In Biotech

Drug Trial Radar · NCT05631626

Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.

A Phase 3, Dose-Optimized, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Parallel Efficacy and Safety Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

26

Actual

Start

Dec 29, 2022

Primary completion

Jun 13, 2023

Study completion Jun 13, 2023

Sponsor

Lead sponsor
Cingulate TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Rho, Inc.
First posted
Nov 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in adults with ADHD in a laboratory classroom setting.

Conditions

  • ADHD
  • ADHD - Combined Type
  • Attention Deficit Hyperactivity Disorder Combined
  • Attention Deficit Hyperactivity Disorder

Interventions

  • CTx-1301 - Dexmethylphenidate 25mgDrug

    25mg CTx-1301 (Dexmethylphenidate tablet)

  • CTx-1301 - Dexmethylphenidate 37.5mgDrug

    37.5mg CTx-1301 (Dexmethylphenidate tablet)

  • CTx-1301 - Dexmethylphenidate 50mgDrug

    50mg CTx-1301 (Dexmethylphenidate tablet)

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Primary Efficacy Analysis Will Analyze the Change in PERMP Scores From Baseline (Pre-dose) at Visit 8 to Hour 16 at Visit 8.Time frame: Average of the change of the PERMP-C scores from baseline defined as pre-dose score at Visit 8 which was at end of 7-day double-blind period to PERMP-C scores at hour 16 at Visit 8.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Research of Southern Nevada, LLC

    Las Vegas, Nevada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.